-
Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)
(PA-20-144)
National Institute of Mental Health
National Institute on Drug Abuse
Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
-
Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)
(PA-20-145)
National Institute of Mental Health
Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
-
NIDA Small Research Grant Program (R03 Clinical Trial Required)
(PA-20-146)
National Institute on Drug Abuse
Application Receipt Date(s): Standard dates apply.
The first standard due date for this FOA is June 16, 2020.
-
Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R01- Clinical Trial Not Allowed)
(PAR-20-147)
National Institute on Drug Abuse
Application Receipt Date(s): October 13, 2020, March 15, 2021, October 13, 2021, March 15, 2022, October 13, 2022, March 15, 2023
-
Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R21- Clinical Trial Not Allowed)
(PAR-20-148)
National Institute on Drug Abuse
Application Receipt Date(s): October 13, 2020, March 15, 2021, October 13, 2021, March 15, 2022, October 13, 2022, March 15, 2023 Standard dates apply.
The first standard due date for this FOA is October 5, 2020
-
NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)
(PAR-20-150)
National Institute on Minority Health and Health Disparities
National Library of Medicine
Application Receipt Date(s): Standard dates apply.
The first standard due date for this FOA is June 16, 2020.
-
Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional)
(RFA-AI-20-007)
National Institute of Allergy and Infectious Diseases
Application Receipt Date(s): August 28, 2020
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Long Acting Treatments for HIV and HIV-Associated Co-Infections (R61/R33 Clinical Trial Not Allowed)
(RFA-AI-20-024)
National Institute of Allergy and Infectious Diseases
Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
-
Exploiting in vivo or in situ imaging approaches to understand HIV-relevant processes in the context of substance use disorders (R61/R33 Clinical Trials Optional)
(RFA-DA-21-005)
National Institute on Drug Abuse
Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
-
Special Topic Research Education Course: Exploring Auditory and Vestibular Biology (R25 - Clinical Trial Not Allowed)
(RFA-DC-20-001)
National Institute on Deafness and Other Communication Disorders
Application Receipt Date(s): June 26, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
-
Revolutionizing Innovative, Visionary Environmental Health Research (RIVER) (R35 Clinical Trial Optional)
(RFA-ES-20-009)
National Institute of Environmental Health Sciences
Application Receipt Date(s): June 18, 2020
-
Polygenic Risk Score (PRS) Methods and Analysis for Populations of Diverse Ancestry Centers (U01 Clinical Trial Not Allowed)
(RFA-HG-20-001)
National Human Genome Research Institute
National Cancer Institute
Office of Research on Women's Health
Application Receipt Date(s): June 23, 2020
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s)
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Polygenic Risk Score (PRS) Methods and Analysis for Populations of Diverse Ancestry Coordinating Center (U01 Clinical Trial Not Allowed)
(RFA-HG-20-002)
National Human Genome Research Institute
Application Receipt Date(s): June 23, 2020
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s)
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.